Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PF-06414300 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| PF-06414300 | EXPERIMENTAL | Participants will receive single or multiple ascending oral doses of PF-06414300 |
| Placebo | PLACEBO_COMPARATOR | Participants will receive matching placebo. |
| Name | Type | Description |
|---|---|---|
| PF-06414300 | DRUG | Participants will receive oral ascending doses. |
| Placebo | DRUG | Participants will receive matching placebo. |
Inclusion Criteria: * Body mass Index (BMI) of 16-32 kg/m2; and a total body weight \>50 kg (110 lb). * Male and female participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, vital signs assessments, 12-lead ECGs a...
PF-06414300 is an investigational small molecule being developed by Pfizer, Inc. (PFE). It is currently in Phase 1 clinical development, studied in healthy participants. The drug is not approved and remains under investigation.
PF-06414300 is being studied in healthy participants as part of early clinical research. Its intended therapeutic use has not been established, as it is still in Phase 1 development.
PF-06414300 is being developed by Pfizer, Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker PFE.
PF-06414300 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities.
PF-06414300 has one completed Phase 1 trial, NCT06659250, which studied how different amounts and forms of the drug act in healthy adults. The trial enrolled 63 participants in the United States.
No, PF-06414300 is not FDA approved. It is an investigational drug currently in Phase 1 clinical development, and its safety and efficacy have not been established.